Clinical Trial

IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial

Study acronym: IAT-MeVO
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
IAT-MeVO is an international, multicenter, prospective, randomised, open-label, blinded end-point assessed (PROBE) trial, to evaluate the efficacy and safety of endovascular therapy (EVT) \[intra-arterial thrombolysis (IAT)-based\] versus best medical management (BMT) in patients with acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) who are ineligible for intravenous thrombolysis (IV) within 24 h of onset.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-04.
Trial Details
NCT Number NCT07336927
Lead Sponsor Bo Wu
Collaborators: West China Hospital, Mianyang Central Hospital, Chengdu First People's Hospital, Sichuan Provincial People's Hospital, Deyang People's Hospital, Suining Central Hospital, The Second People's Hospital of Chengdu
Conditions Acute Ischemic Stroke Due to Medium-vessel-occlusion
Enrollment 614 participants
Start Date 2026-01-01
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-15